A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Atezolizumab (Primary) ; Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 27 Sep 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 27 Sep 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 17 Apr 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.